Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Diagnosed with nHCM (hypertrophied and non-dilated left ventricle in absence of systemic or other known cause), with LV wall thickness ≥ 15mm at Screening or ≥ 13mm with a positive family history of HCM.~* Age 18 and greater, Body weight \> 45kg~* Documented LVEF ≥ 55% at the Screening as determined by echo central lab~* LVOT gradient \< 30 mmHg at rest AND during Valsalva AND post-exercise~* NYHA functional class II or III~* Elevated NT-proBNP at rest~Key Exclusion Criteria:~* History of syncope, sustained ventricular tachyarrhythmia with exercise, obstructive coronary artery disease or myocardial infarction within the past 6 months~* History of resuscitated sudden cardiac arrest at any time or known appropriate implantable cardioverter defibrillator (ICD) discharge within 6 months prior to Screening~* Current treatment with disopyramide or ranolazine (within 14 days prior to Screening)~* Current or planned treatment during the study with a combination of beta-blockers and calcium channel blockers~* Has been treated with invasive septal reduction (surgical myectomy or percutaneous alcohol septal ablation \[ASA\]) within 6 months prior to Screening~* History of resting or post-exercise LVOT \>30 mmHg unless subsequently treated by septal reduction~* Has QTc Fridericia (QTcF) \>480 ms or any other ECG abnormality considered by the investigator to pose a risk to participant safety (eg, second-degree atrioventricular block type II)~* Has persistent or permanent atrial fibrillation not on anticoagulation for at least 4 weeks prior to Screening and/or not adequately rate-controlled within 1 year of Screening~* History of clinically significant malignant disease within 10 years such as non-metastatic cutaneous squamous cell or basal cell carcinoma~* History or evidence of any other clinically significant disorder, condition, or disease that, in the opinion of the investigator or MyoKardia physician, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Active Treatment for participants with base target trough concentration
- Group 2 (Type: EXPERIMENTAL): Active Treatment for participants with higher target trough concentration
- Placebo (Type: PLACEBO_COMPARATOR): Placebo Group

Based on this trial design, predict the completion outcome and termination type (if applicable).